Semaglutide patent loss opens up a $6 billion opportunity for Indian generic drug makers ADVERTISEMENT The world's second-largest-selling drug - Novo Nordisks anti-diabetes/weight management drug semaglutide (branded as Ozempic and Wegovy) - is set to lose patent protection in several countries this year, including in India, China, Canada, and Brazil, starting in the fourth week of March
Elevated plasma phenylalanine predicts mortality in critical patients with heart failure
(Toradol, Zofran, Benadryl) Rapid Hydration $120 1 liter of pH balanced fluid and electrolytes Curcumin $200 A natural anti-inflammatory found in curry, the Indian spice
Phase 3 Trials Design and Patient Population The study analyzed results from the evoke and evoke+ trials, two large multicenter, randomized, placebo-controlled phase 3 trials conducted across 566 sites in 40 countries
Enzymatic activity in Turkey, duck, quail and chicken liver microsomes against four human cytochrome P450 prototype substrates and aflatoxin B1